Beractant is a pulmonary surfactant used for the treatment and prevention of Respiratory Distress Syndrome (RDS) in premature infants. Considered a natural source of surfactant as it is made from bovine lung extract, beractant contains a mixture of phospholipids, neutral lipids, fatty acids, and surfactant-associated proteins such as SP-B and SP-C.
- Mechanism
- Curator reviewed
Beractant replenishes lung surfactant and restores surface activity to the lungs by lowering surface tension on alveolar surfaces during respiration and stabilizing the alveoli against collapse at resting transpulmonary pressures.
- Primary indication
- Beractant is indicated for prevention and treatment of Respiratory Distress Syndrome (RDS) in premature infants.Curator reviewed · 1 structured indication
- First approval
- Canada, 2012 · United States, 1991
- Also known as
- Beraksurf
- Code names
- A-60386X
- Brand names
Resolves to
What you can answer from here — as of July 03, 2026
Which drugs share a target with Beractant, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account